Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Kadmon Corporation, LLC manages a portfolio with 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 6 distinct examiners, ensuring that each matter is reviewed by a different individual. This high level of examiner diversity suggests a broad range of technical scrutiny for the company's applications.
The prosecution activity is spread across 5 distinct art units. This distribution indicates that the company's Biotechnology & Pharmaceuticals filings cover a wide array of sub-specialties within the USPTO. HASTINGS, ALISON AZAR is identified as the busiest examiner, though they are only responsible for 1 busiest examiner pending office action.
For a practitioner, the fact that 6 distinct examiners are involved across 5 distinct art units means that prosecution strategies cannot be easily generalized. Each of the 6 pending office actions likely requires a tailored approach based on the specific art unit and examiner. The workload is evenly distributed, as the busiest examiner only handles one pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| KOSTURKO, GEORGE W | 1 | 54.7% | +49.0% |
| MCANANY, JOHN D | 1 | 67.2% | +43.7% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 132d overdue |
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | — |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | — |
| 18548678 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | MCANANY, JOHN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 132d overdue |
| 18059548 | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins | LU, CHENG | 11d overdue |
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | — |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | — |
| 18548678 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | MCANANY, JOHN D | — |
| 16812867 | IMMUNOMODULATORY AGENTS | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857543 | Belumosudil for Treating Chronic Lung Allograft Dysfunction | HASTINGS, ALISON AZAR | — | §102§103§112 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18618767 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease in Patient Subpopulations | KOSTURKO, GEORGE W | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18548678 | USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY | MCANANY, JOHN D | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ANDERSON, REBECCA L | 1626 | §102§103 | Final Rejection | 132d overdue | Pending | Feb 01, 2023 |
| 18059548 | B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins | LU, CHENG | 1642 | §112 | Non-Final OA | 11d overdue | Pending | Nov 29, 2022 |
| 16812867 | IMMUNOMODULATORY AGENTS | GAO, ASHLEY HARTMAN | 1678 | §103Other | Final Rejection | — | Pending | Mar 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial